MAYO CLINIC
Mayo Medical Laboratories

METHOD CHANGE
NOTIFICATION DATE: November 4, 2011
EFFECTIVE DATE: November 7, 2011

Lung Cancer, *ALK* (2p23) Rearrangement, FISH, Tissue #60619

EXPLANATION: Mayo Medical Laboratories' ALK gene rearrangements test (FLCA) will now use the FDA-approved Vysis ALK Break Apart FISH Probe. This enables the test to be used as a companion diagnostic test for the drug Xalkori (crizotinib), which the FDA recently approved to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) that harbor anaplastic lymphoma kinase (ALK) gene rearrangements.

LIST FEE: $560.40 (NO CHANGE)

CURRENT CPT CODES:
88271 x 2-DNA Probe
88275-Interphase in situ hybridization
88291-Interpretation and report

NEW CPT CODES:
88271 x 2-DNA Probe
88274-Interphase in situ hybridization, analyze 25-99 cells
88291-Interpretation and report

NOTE: This change may impact test set-up information and could require a change to file definition. Please review the Test Set-Up information for specifics at http://www.mayomedicallaboratories.com/test-notifications/index.html.

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager or
Marvin H. Anderson, Jr., MML Laboratory Technologist Resource Coordinator
Telephone: 800-533-1710